In anesthetized pigs human chorionic gonadotropin increases myocardial perfusion and function through a ␤-adrenergic-related pathway and nitric oxide. J Appl Physiol 115: 422-435, 2013. First published June 20, 2013 doi:10.1152/japplphysiol.00425.2013.-Human chorionic gonadotropin (hCG) is not only responsible for numerous pregnancy-related processes, but can affect the cardiovascular system as well. So far, however, information about any direct effect elicited by hCG on cardiac function, perfusion, and the mechanisms involved has remained scarce. Therefore, the present study aimed to determine the primary in vivo effect of hCG on cardiac contractility and coronary blood flow and the involvement of autonomic nervous system and nitric oxide (NO). Moreover, in coronary endothelial cells (CEC), the intracellular pathways involved in the effects of hCG on NO release were also examined. In 25 anesthetized pigs, intracoronary 500 mU/ml hCG infusion at constant heart rate and aortic blood pressure increased coronary blood flow, maximum rate of change of left ventricular systolic pressure, segmental shortening, cardiac output, and coronary NO release (P Ͻ 0.0001). These hemodynamic responses were graded in a further five pigs. Moreover, while blockade of muscarinic cholinoceptors (n ϭ 5) and of ␣-adrenoceptors (n ϭ 5) did not abolish the observed responses, ␤1-adrenoceptors blocker (n ϭ 5) prevented the effects of hCG on cardiac function. In addition, ␤2-adrenoceptors (n ϭ 5) and NO synthase inhibition (n ϭ 5) abolished the coronary response and the effect of hCG on NO release. In CEC, hCG induced the phosphorylation of endothelial NO synthase through cAMP/PKA signaling and ERK1/2, Akt, p38 MAPK involvement, which were activated as downstream effectors of ␤2-adrenoceptor stimulation. In conclusion, in anesthetized pigs, hCG primarily increased cardiac function and perfusion through the involvement of ␤-adrenoceptors and NO release. Moreover, cAMP/PKA-dependent kinases phosphorylation was found to play a role in eliciting the observed NO production in CEC. adrenergic receptors; cardiac perfusion; cardiac function; gonadotropins; nitric oxide HUMAN CHORIONIC GONADOTROPIN (hCG) is a glycoprotein hormone and, like the other members of the gonadotropin family [follicle stimulating hormone and luteinizing hormone (LH)], it has two nonidentical and noncovalently linked peptide chains designated ␣-and ␤-subunits (15).
HUMAN CHORIONIC GONADOTROPIN (hCG) is a glycoprotein hormone and, like the other members of the gonadotropin family [follicle stimulating hormone and luteinizing hormone (LH)], it has two nonidentical and noncovalently linked peptide chains designated ␣-and ␤-subunits (15) .
hCG is secreted in large quantities by syncytiotrophoblasts and is involved in pregnancy implantation and placental development (28) . In relation to its known physiological activities, hCG has been commonly administrated, together with gonadotropin-releasing hormone and LH/follicle stimulating hormone, as ovarian hyperstimulator in fertility treatment (18) .
hCG, as well as LH, binds to a membrane receptor made up of a single polypeptide chain, which is coupled to a Gs protein complex and stimulates the activity of adenylate cyclase (3) . Also, nitric oxide (NO) has been found to be involved in the effects of hCG on regulation of blood-follicle barrier and ovulation (17, 34) . Moreover, an hCG-dependent increase in NO production has been reported in murine microglia and peritoneal macrophages (22, 23) .
In addition to its function as regulator of pregnancy-related events, hCG has direct angiogenic functions on hCG/LH receptor-expressing uterine endothelial cells that responded with increased capillary formation in vitro and on neovascularization. Moreover, previous studies were able to demonstrate the existence of hCG/LH receptors in vascular endothelium and vascular smooth muscle in tissue other than the reproductive system (1, 15) . For instance, hCG has been found to act as a potent vasodilator, not only in arteries of the genital tract, but also in vessels that have an important impact on systemic blood pressure, such as the mesenteric arteries (15) . However, the available information on its cardiac effects has been scarce and more related to the response to ovarian hyperstimulation treatment than to a direct action of hCG (38) . Hence during ovarian hyperstimulation syndrome (OHSS), the observed life-threatening complication occurring in stimulated ovarian cycles of tachycardia and increased cardiac function has not been directly related to hCG (7) .
The present study was, therefore, planned in controlled experiments in anesthetized pigs to investigate the primary in vivo effects of hCG on cardiac function and perfusion and the mechanistic involvement of autonomic nervous system and of NO.
MATERIAL AND METHODS

In vivo
Ethical approval. The experiments were carried out in accordance with Guiding Principles in the Care and Use of Vertebrate Animals in Research and Training, the national guidelines (DLGS 27/01/1992, licence no. 116), and with the approval of the local Ethical Committee.
Animal's instrumentation and measurements. The experiments were carried out in 35 domestic pigs, weighing 65-75 kg, supplied by an accredited dealer (Azienda Cornelia, San Pietro Mosezzo, Novara, Italy). After being fasted overnight, pigs were anesthetized with intramuscular ketamine (20 mg/kg, Parke-Davis, Detroit, MI), followed after ϳ15 min by intravenous sodium pentobarbitone (15 mg/kg, Siegfried, Zofingen, Switzerland), and artificially ventilated with oxygen-enriched air using a respiratory pump (Harvard 613; Harvard Apparatus, South Natick, MA). Anesthesia was maintained throughout the experiments by a continuous intravenous infusion of sodium pentobarbitone (7 mg·kg Ϫ1 ·h Ϫ1 ) and assessed as previously reported (25) . Pressures in the ascending aorta and right atrium were recorded via catheters connected to pressure transducers (Statham P23 XL; Gould, Valley View, OH) inserted, respectively, into the right femoral artery and right external jugular vein. The chest was opened in the left fourth intercostal space, the pericardium was cut, and an ultrasound flowmeter probe (model 420; Transonic Systems, Ithaca, NY) was positioned around the proximal part of the left anterior descending coronary artery (LAD) to record coronary blood flow. Left ventricular pressure was measured using a catheter connected to a pressure transducer (Gould) inserted through the left atrium. To pace the heart, electrodes were sewn on the left atrial appendage and connected to a stimulator (model S8800; Grass Instruments, Quincy, MA), which delivered pulses of 3-5 V for 2-ms duration at the required frequency. To assess regional contractile function, pairs of 2-mm ultrasonic segment length microtransducer crystals (Sonometrics, London, Ontario, Canada) were implanted in the left anterior ventricular wall in the distribution area of the LAD, ϳ10 mm apart and parallel to the direction of the fibers, so that the segmental shortening was in line with the orientation of fibers. Two additional crystals were placed at opposite ends of the left ventricular short axis to measure changes in ventricular dimension throughout cardiac cycles (11) (12) (13) (14) . Arterial blood samples were used to measure pH, arterial pressure of oxygen and carbon dioxide (PO 2 and PCO2) (with a gas analyzer; Radiometer ABL505, Copenhagen, Denmark) and the hematocrit. Sampling of blood from the LAD and the anterior interventricular vein allowed the measurement of coronary arterial and venous PO2 and arteriovenous oxygen content. Coronary venous blood samples were also taken for NO detection by Griess system (Promega, Madison, WI). The acid-base status of the animals was kept within normal limits, as previously reported (25) . Infusions into the LAD and the left femoral vein were performed using a catheter connected to a butterfly needle inserted into the coronary artery distal to the flowmeter probe and through a catheter inserted into the left femoral vein. To prevent changes of arterial blood pressure, a pressurized reservoir connected to the arterial system was used, as previously described (11) (12) (13) (14) . Coagulation of the blood was avoided by intravenous injection of heparin (Parke Davis; initial doses of 500 IU/kg, and subsequent doses of 50 IU/kg every 30 min). The rectal temperature of the pigs was monitored and kept between 38 and 40°C using an electric pad. Hemodynamic variables were monitored and recorded together with heart rate and the maximum rate of change of left ventricular systolic pressure (dP/dtmax) by using a micro1401 A/D converter (Cambridge Electronic Design, Cambridge, UK) displayed on a personal computer and processed by using Spike2 Software (Cambridge Electronic Design).
The dP/dtmax was used to define the timing of the cardiac cycle for segment length measurements with ultrasonic crystals. End-diastolic length was measured at the onset of the rapid increase in dP/dtmax, and end-systolic length was measured at peak negative dP/dtmax. Enddiastolic and end-systolic ventricular volumes were obtained from data of end-diastolic and end-systolic lengths through the specific software (Sonometrics). Percentage of segmental shortening (%SS) was calculated using the formula: %SS ϭ (end-diastolic length Ϫ end-systolic length) ϫ 100/end-diastolic length.
The data from using the Sonomicrometer crystals were digitally processed by specific hardware and software (Sonometrics). Cardiac output was derived using the Sonosoft System from data recorded by piezoelectric crystals. To calculate coronary vascular resistance, the difference between mean aortic blood pressure and mean left ventricular pressure during diastole was considered as the coronary pressure gradient. Coronary vascular resistance was calculated as the ratio between this pressure gradient and mean diastolic coronary blood flow during the steady state. At the end of the experiment, each animal was killed by an intravenous injection of 90 mg/kg pentobarbitone sodium.
In Vitro
Cell culture. Coronary endothelial cells (CECs) were obtained using coronary arteries isolated from pigs, as previously described (10) . CECs were cultured into 0.1% gelatin-coated 100-mm culture dish with endothelial growth media-2 (EGM-2; Lonza, Basel, Switzerland), supplemented with 1% penicillin-streptomycin-glutamine (Sigma, Milan, Italy) and maintained at 37°C with 5% CO2. In the set of experiments used for the Griess assay, 1 ϫ 10 5 cells were plated in 0.1% gelatin-coated 24-well plates with EGM-2 complete medium for 24 h at 37°C with 5% CO 2. At the end of this time, cells were washed and maintained for 4 -6 h in DMEM (Sigma), supplemented with 1% penicillin-streptomycin-glutamine (Sigma) without fetal calf serum and red phenol (starvation medium). For Western blot analysis, cells were plated on 0.1% gelatincoated dishes with starvation medium for 8 h.
EXPERIMENTAL PROTOCOL
In vivo
The experiments were begun after at least 30 min of steady-state conditions. Preliminary experiments were performed in five pigs to examine the effects of intravenous hCG on hemodynamic variables. In those animals, either hCG (Sigma, Milan, Italy) dissolved in saline or saline only was infused over 5 min in the left femoral artery by means of an infusion pump (model 22; Harvard Apparatus, South Natick, MA), working at constant rate of 1 ml/min. The infused hCG dose amounted to 500 mU for each milliliter per minute of measured cardiac output. This dose was similar to the plasma hCG concentration found in pregnancy (15) and during intramuscular single dose of 10,000 IU hCG for fertility treatment (4) . When the effects of hCG were over, hCG was readministered in the same five pigs, while preventing changes in arterial blood pressure.
In the other 25 pigs, the direct effects of hCG on cardiac perfusion and function were examined by infusing either hCG dissolved in saline or saline only into the LAD over 5 min through the infusion pump. The infused dose was the same as that used in preliminary experiments, amounting to 500 mU for each milliliter per minute of measured coronary blood flow, to achieve an intracoronary hCG concentration of ϳ1 M. In these animals, the heart was paced to a frequency higher, by 20 beats/min, than that observed during the steady state, and the arterial system was connected to the pressurized reservoir. Moreover, coronary artery and venous plasma samples were taken for measurement of PO2, oxygen, and NO content.
In a further five pigs, the effects of graded administration of hCG were examined by infusing the hormone at 8 subsequent doses of 0.1, 1, 10, 50, 100, 500, 1,000, and 1,500 mU/ml. Each dose was infused for 5 min and calculated in relation to measured coronary blood flow.
Recordings taken for 10 min during the steady-state before infusion of hCG at either uncontrolled variables or at constant heart rate and aortic blood pressure were used as control. Measurements of hemodynamic variables, coronary artery and coronary venous PO2, and oxygen content were obtained during the last 30 s of infusion in the steady state and compared with control values. Myocardial oxygen consumption (ml O2·min Ϫ1 ·100 g
Ϫ1
) was calculated as the product of coronary arteriovenous oxygen content and coronary blood flow. Moreover, NO content in coronary venous blood was measured, as previously described (12) (13) (14) 31) , following the same time course described for PO2 and oxygen content, and values were compared with control ones.
In the 25 pigs, the role of muscarinic cholinoceptors and ␣-and ␤-adrenoceptors was examined throughout by repeating 500 mU/ml intracoronary hCG administration after the intravenous administration of muscarinic cholinoceptors blocker atropine sulfate (0.5 mg/kg, Sigma, n ϭ 5), ␣-adrenoceptors blocker phentolamine (1 mg/kg, Sigma, n ϭ 5), ␤ 1-adrenoceptors blocker atenolol (1 mg/kg, Sigma, n ϭ 5) and ␤ 2-adrenoceptors blocker butoxamine (2.5 mg/kg, Sigma, n ϭ 5). The involvement of NO synthase (NOS) was examined by repeating hCG infusion after intracoronary administration of the NOS inhibitor, N G -nitro-Larginine methyl ester (L-NAME; 2 mg for each milliliter per minute of measured coronary blood flow, Sigma, n ϭ 5).
The effect of blocking agents and of hCG on NO release, coronary artery and coronary venous PO 2, and myocardial oxygen consumption was examined by repeating the measurements after each blocker or hCG infusion in the steady state and comparing the values with those taken immediately beforehand.
All drugs were given without pacing the heart or controlling aortic pressure to assess their effects on baseline hemodynamic variables in the steady state. Thereafter, heart rate and aortic blood pressure were kept constant, and measured hemodynamic variables were taken as "control". In all subsequent experiments, the effects of hCG in the presence of blocking agents were examined while preventing changes in heart rate and aortic blood pressure. Changes of hemodynamic variables caused by various agents were compared with control values.
Finally, at the end of experiments, the expression of LH/hCG receptors was analyzed both in fragments of myocardium and LAD taken in each animal.
In Vitro
Assay of NO production. NO production was measured in CEC culture supernatants using the Griess method (Promega, Madison, WI) following the manufacturer's instruction. Cells plated into 0.1% gelatin-coated 24-well plates in starvation medium were treated with hCG (10 Ϫ9 -10 Ϫ5 M) alone or in the presence of L-NAME (10 mM, Sigma), the selective ␤2-adrenoceptor agonist and antagonists salbutamol (1 nM to 10 M, Sigma) and butoxamine (100 M, Sigma), the selective ␤1-adrenoceptor agonist denopamine (1 nM to 10 M, Sigma), the adenylyl cyclase agonist and antagonist forskolin (1 M, Sigma) and 2=5=-dideoxyadenosine (1 M, Sigma), the selective inhibitor of cAMP-dependent protein kinase H89 (1 M, Sigma), the p38 MAPK inhibitor SB-203580 (1 M, Promega), the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin (100 nM, Sigma), and the MEK1 inhibitor U-0126 (10 M, Promega). In the same experiments, acetylcholine chlorhydrate (10 M, Sigma) was used as a positive control. These agonists and antagonists and their vehicles were tested in basal medium without agents as well. At the end of stimulations, NO production in the sample's supernatants was examined through the addition of an equal volume of Griess reagents (9, (12) (13) (14) , and the absorbance at 570 nm was measured by a spectrometer (BS1000 Spectra Count, San Jose, CA). NO production was quantified with respect to the nitrate standard curve and expressed as a percentage.
Myocardium and coronary arteries lysates.
To analyze the expression of LH/hCG receptors in the myocardium and coronary vessels, 50 mg of each tissue sample, maintained at Ϫ80°C before being used, were washed in an iced saline solution and lysed in an iced buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1% Triton X-100, 10 mM EDTA, 0.05% NP-40; Sigma), supplemented with 1:100 protease inhibitors cocktail, 1:100 sodium orthovanadate, 0.1 M sodium fluoride, and 1:1,000 phenylmethylsulfonyl fluoride (Sigma). The extracted proteins were quantified through a bicinchoninic acid protein (Pierce, Rockford, IL), and after a reduction by Laemmli buffer ϫ5 (Sigma) they were used for electrophoresis and immunoblot experiments.
Cell lysates. CECs were plated in 0.1% gelatin-coated dishes with EGM-2 complete medium, and at confluence they were incubated with starvation medium for 8 h at 37°C with 5% CO2 and then stimulated in the same conditions and with the same agents used for the Griess method. After the stimulations, cells were washed and lysed in iced RIPA buffer (50 mM HEPES, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, and 1 mM sodium fluoride; Sigma) supplemented with 1:200 sodium orthovanadate (Sigma) and 1:100 protease inhibitor cocktail (Sigma). The extract proteins were quantified through a bicinchoninic acid protein assay (Pierce), and after a reduction by Laemmli buffer ϫ5 (Sigma) they were used for electrophoresis and immunoblot experiments.
Western blot analysis. Cell lysates (30 g protein for each sample) and tissue lysates (40 g protein for each sample) were resolved on 10 and 7% SDS-PAGE gels (Bio-Rad Laboratories, Hercules, CA), respectively, and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories), which were incubated overnight at 4°C with specific primary antibodies: anti-phospho-PKA (1:1,000; Santa-Cruz Biotechnology, Santa-Cruz, CA); anti-phospho-ERK (1:1.000, Thr202/Tyr204, Cell Signaling Technologies, Beverly, MA), anti-phospho-Akt (1:1,000, Ser473, Cell Signaling Technologies), anti-phospho-p38 (1:1.000, Thr180/Tyr182, Cell Signaling Technologies), anti-phospho-endothelial NOS (eNOS; 1:1,000, Ser1177, Cell Signaling Technologies), and anti-LH/hCG (1:500, Santa Cruz). Phosphorylated protein expression was normalized through ␤-actin (1:5,000, Sigma) detection.
Statistical Analyses
All data were recorded using the Institution's database. Statistical analysis was performed by using STATVIEW version 5.0.1 for Microsoft Windows (SAS Institute, Cary, NC). Data were checked for normality before statistical analysis. In the in vivo experiments, Student's paired t-test was used to examine changes of measured variables within each animal before and after any treatment. One-way ANOVA followed by Bonferroni post hoc tests were used to compare differences among groups of animals. Nonparametric Wilcoxon signed-rank test was used to compare significance of percent changes before and after blockers. Cohen's d was used for analysis of changes of coronary venous PO 2, arteriovenous oxygen content, and myocardial oxygen consumption. Regarding the in vitro experiments, all results were obtained from five different cell cultures for each experimental protocol. The results obtained were examined through twoway ANOVA followed by a Bonferroni post hoc test. All data are presented as means Ϯ SD (minimum and maximum values). A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
In vivo
In all pigs, recordings commenced ϳ5 h after induction of anesthesia. The mean (range) pH, PO 2 , and PCO 2 of arterial blood were 7.4 Ϯ 0.012 (7.39 -7.44), 118.9 Ϯ 11.5 (100 -138) Torr, and 40.2 Ϯ 1 (39 -42) Torr, and the hematocrit was 39.2 Ϯ 1% (39 -41).
Intravenous administration of 500 mU/ml of measured coronary blood flow hCG caused a reduction of arterial blood pressure and an increase of heart rate, coronary blood flow, and dP/dt max (P Ͻ 0.05; Fig. 1 ). No effects were observed during saline infusion. When arterial blood pressure was kept constant, the increase of heart rate was similar to that observed beforehand (5.8 Ϯ 2 beats/min from control values of 81.2 Ϯ 7.1 beats/min; P Ͻ 0.05).
The hemodynamic responses to hCG began within ϳ2 min after starting the infusion and were over within 5 min after the end of infusion. Changes of right atrial pressure and left ventricular pressure were not significant.
Responses to intracoronary infusion of hCG.
In each pig, intracoronary infusion of hCG caused an increase in mean coronary blood flow, dP/dt max , cardiac output, and %SS of ϳ35, 20, 17, and 24% of control values (P Ͻ 0.0001; Fig. 2 ; Table 1 ). The increase in coronary blood flow was accompanied by a decrease of coronary vascular resistance of ϳ35% (P Ͻ 0.0001; Table 1 ) and by increases of myocardial oxygen consumption and NO release of ϳ30 and 73%, respectively (P Ͻ 0.0001; Table 1 ). Cohen's d showed a huge effect on myocardial oxygen consumption (Cohen's d: 2.25), whereas a small effect on arteriovenous oxygen content was found (Cohen's d: 0.33). The effects of hCG began within ϳ90 s after starting the infusion, reached a steady state in ϳ2 min, and were over within 5 min after the end of infusion. The intracoronary infusion of the vehicle did not affect hemodynamic variables.
Dose-response study. In the five pigs, intracoronary infusion of eight doses of hCG caused a dose-response effect on coronary blood flow, cardiac function, and NO release (Fig. 3) . The control values of mean (range) coronary blood flow, dP/dt max , cardiac output, and %SS, respectively, were 69.4 Ϯ 7.8 (58 -77) ml/min, 2,068 Ϯ 194.5 (1,820 -2,266) mmHg/s, 5,790 Ϯ 341.3 (5,356 -6,300) ml/min, and 14.54 Ϯ 0.96% (13-15.3) . The threshold dose of the hormone was found between the doses of 0.1 and 1 mU/ml. Tables 2 and 3 show the effects of blocking agents and of hCG given after the blocking agents on hemodynamic variables. In Table 3 , coronary venous PO 2 , arteriovenous oxygen content, and myocardial oxygen consumption before and after atenolol, butoxamine, and L-NAME and after hCG given in animal treated with the above agents are reported as well.
Mechanisms of the responses.
In the 10 pigs, blockade of muscarinic cholinoceptors (n ϭ 5) and ␣-adrenoceptors (n ϭ 5) did not affect either the coronary and cardiac responses or the NO release caused by the intracoronary infusion of hCG (Table 2 ; Fig. 4) .
After giving the adrenoceptors blocker atenolol (n ϭ 5), the increase of coronary blood flow and NO caused by hCG was similar to that observed before atenolol (Fig. 4) , whereas hCG failed to affect cardiac function (Table 3 , Fig. 4) . Moreover, the insignificant or small effects on coronary venous PO 2 and arteriovenous oxygen content changed into large/huge responses (Cohen's d, 1.17 and 56) .
In pigs treated with ␤ 2 -adrenoreceptors blocker butoxamine (n ϭ 5) and NOS inhibitor L-NAME (n ϭ 5), the effects of hCG on coronary blood flow and NO release were abolished in the absence of significant changes of responses of cardiac function (Table 3 ; Fig. 4 ). In addition, the insignificant or small effects of hCG on coronary venous PO 2 and arteriovenous oxygen content changed into huge responses In Vitro hCG induces dose-dependent NO release. The effects of hCG on NO release were examined in CECs cultured and maintained as described in MATERIALS AND METHODS. The time course analysis showed that the maximum effect on NO release was after 90-s stimulation; this was used for all successive experiments (Fig. 5A) .
In addition, hCG (10
Ϫ9
-10 Ϫ5 M) caused a dose-dependent NO release that reached a plateau at concentration higher than 100 nM (Fig. 5B) , which was used for all successive experiments. Values are means Ϯ SD (with range in parentheses). hCG, human chorionic gonadotropin; HR, heart rate; ABP, mean aortic blood pressure; dP/dtmax, maximum rate of change of left ventricular systolic pressure; RAP, mean right atrial pressure; LVEDP, left ventricular end-diastolic pressure; CBF, mean coronary blood flow; CVR, coronary vascular resistances; CO, cardiac output; %SS, percentage of segmental shortening; NO, nitric oxide; PvcO2, coronary sinus partial pressure of oxygen; a-vCO2, coronary arteriovenous oxygen content; MV O2, myocardial oxygen consumption. *P Ͻ 0.0001 vs. control (taken before hCG administration at constant HR and ABP).
Signaling involved in NO production caused by hCG. As depicted in Fig. 6A , the effects of 100 nM hCG on NO release were increased by costimulation with forskolin and salbutamol (P Ͻ 0.05), but not by costimulation with denopamine (Fig. 6C) .
To clarify the role of cAMP-PKA in the effects of hCG, CECs were treated with an agonist and antagonist of the adenylyl cyclase-related pathway. Forskolin (1 M) was able to potentiate the effects of 100 nM hCG, when given in costimulation. In addition, in CECs pretreated with either 1 M 2=,5=-dideoxyadenosine and 1 M H89, all effects were abolished (P Ͼ 0.05).
To examine the possible role of ␤-adrenergic signaling in NO release caused by hCG, experiments were performed in the presence of ␤-adrenoceptor agonist and antagonist. In CECs, 10 M salbutamol were able to amplify the effects of 100 nM hCG on NO production when given in costimulation (P Ͻ 0.05; Fig. 6A ). It is also noteworthy that those effects were dose dependent, as the response of CEC to hCG increased up to salbutamol concentration similar to those that have been considered to occupy ␤ 2 -adrenoceptors (21).
In the presence of 100 M butoxamine, the response of CECs to hCG was abolished (P Ͼ 0.05). Moreover, the adenylyl cyclase and PKA inhibitors were able to prevent the response of cells to hCG also when given in costimulation with salbutamol. Finally, in CECs, the role of PI3K/Akt, ERK/MAPK, and p38/MAPK pathways was examined through preincubation for 15 min with specific PI3K, MEK1, and p38 inhibitors (100 nM wortmannin, 10 M U-0126, and 1 M SB-203580, respectively). In the presence of those agents, the effects of hCG alone or in costimulation with the agonists used before were abolished ( Fig. 6B ; P Ͼ 0.05).
Intracellular pathways activated by hCG. As shown in Figs. 7 and 8, in CEC treated with 100 nM hCG for ϳ90 s, an increased phosphorylation of PKA, Akt, p38 MAPK, and ERK1/2 was observed. Moreover, in the presence of 1 M forskolin and 10 M salbutamol alone or in costimulation with 100 nM hCG, the levels of phosphorylation of Akt, ERK, p38, and eNOS were greater than control. Preincubation for 15 min of CECs with 1 M 2=,5=-dideoxyadenosine, 1 M H89, and 100 M butoxamine abolished all effects of hCG. In addition, in the presence of 100 nM wortmannin, 10 M U-0126, and 1 M SB-203580, hCG was not able to cause kinase phosphorylation, confirming the role of PI3K/Akt, ERK/MAPK, and p38/MAPK in the signaling leading to eNOS activation.
DISCUSSION
The present study demonstrates, for the first time, that intracoronary hCG increases coronary blood flow and myocardial contractility through ␤-adrenoceptors in the anesthetized pig. Moreover, NO release was found to be involved in the coronary vasodilation.
hCG is a major trophoblastic peptide hormone that is responsible for numerous pregnancy-related and pregnancy-maintaining processes (15) . In addition to its function in modulation of pregnancyrelated events (28) , hCG has recently been reported to affect the cardiovascular system as well. The detection of functional LH/hCG receptors in endometrial and myometrial blood vessels (24) , as well as in uterine arteries (36) , gave rise to the hypothesis that gonadotropins are vasoactive hormones. Hence, hCG has been found to act as vasodilator in mesenteric arteries (5, 15, 16) . The results of the present study, which are in agreement with the above observations, add new information about cardiovascular effects of hCG. In preliminary experiments performed in anesthetized pigs, intravenous hCG acutely reduced arterial blood pressure and increased heart rate, the latter response being a direct effect of hCG, since it was also present while preventing baroreflex nervous control on heart rate. Moreover, those responses were accompanied by an increase of cardiac perfusion and function without changes in cardiac preload. These findings are consistent with the available information about hemodynamic changes found in women undergoing controlled ovarian hyperstimulation by gonadotropin-releasing hormone/hCG or LH/hCG. In those patients, a decrease of blood pressure and vascular resistance accompanied by an increase of cardiac output has been observed mainly with hCG (26, 27) .
The present results could also have clinical implication when considering the hemodynamic changes observed during OHSS, which have been hypothesized to arise from treatment with hCG.
OHSS is a serious complication of assisted reproductive technologies, with potential for critical morbidity and even death. The circulatory dysfunction found in OHSS could be secondary to the simultaneous occurrence of increased vascular permeability, marked arteriolar vasodilation, arterial hypotension, tachycardia, and increased cardiac output (7) . Since hCG is used to trigger oocyte maturation in ovarian stimulation cycles and manifestations of OHSS occur within a predictable time frame in the presence of hCG, it seems that the administration of hCG at the culmination of a controlled ovarian hyperstimulation cycle is the key event in the induction of OHSS (27) . Moreover, clinical resolution of OHSS seems to parallel the decrease of residual exogenous hCG serum levels after induction of oocyte maturation.
Hence, our data that were obtained by infusing hCG at doses similar to those achieved by intramuscular hCG administration for infertility treatment (4) would, for the first time, suggest a role for hCG in those hemodynamic changes. Thus the findings obtained in the present study add more information about the pathophysiological role played by hCG in OHSS and could be clinically used in the management of patients undergoing treatment for OHSS. In those women, hCG dose and hCG plasma values should be accurately monitored not only during in vitro fertilization/embryo transfer, but throughout pregnancy, especially if patients are treated with agents interfering with the ␤-adrenergic system and/or NO. Indeed, pregnancy, and its associated increase in endogenous hCG, has been reported to prolong or worsen the course of an episode of OHSS or initiate a "late form" of OHSS (27) .
Furthermore, the primary effect of hCG on the coronary circulation and cardiac function was analyzed by performing the experiments in vivo while preventing changes in both heart rate and arterial pressure. Thus the design of the experiments helped to avoid any secondary interference from reflex and physical effects, related to extravascular compressive forces, on the observed responses of the coronary circulation and the related cardiac function (6) . Moreover, the direct relationship between the hormone and its coronary and cardiac response was confirmed during the dose-response study, which showed that the increase in hemodynamic variables could be augmented by increasing the dose of the infused substance from similar concentration found in the first weeks of pregnancy up to those reached toward the end of pregnancy (15) . In addition, since the above effects were accompanied by significant increases of myocardial oxygen consumption, the myocardial response to hCG would be considered as a direct effect of the peptide (37) . Also the absence of a decrease of coronary venous PO 2 , which is an index of myocardial tissue oxygenation that is a balance between oxygen supply and demand (37) , could as well be suggestive of a direct action of hCG on coronary vasculature.
In the same controlled anesthetized animal preparation, neither the blockade of cholinergic receptors nor the administration of phentolamine affected the hemodynamic responses to hCG, indicating that the above effects did not involve cholinergic or ␣-adrenergic receptors. In contrast, the results obtained after butoxamine and atenolol administration showed for the first time the involvement of ␤-adrenoceptors in the cardiovascular effects elicited by intracoronary hCG. Hence, after atenolol, the increase of dP/dt max , cardiac output, and %SS was prevented, whereas the coronary effects were abolished in animals treated with butoxamine only. All blockers were given at the same doses previously used (8, (11) (12) (13) (14) . In addition, the results obtained on coronary venous PO 2 , arteriovenous sinus oxygen content, and myocardial oxygen consumption caused by hCG after blocking agents administration are in support of a direct vasodilatory effect of the hormone (37) . When hCG was given after atenolol, which abolished the effects of the hormone on cardiac contractility, coronary blood flow and coronary venous PO 2 increased while arteriovenous sinus oxygen content decreased at a time when myocardial oxygen consumption did not change. On the contrary, when hCG was infused after butoxamine and L-NAME, which abolished the vascular effects without affecting the cardiac response, the coronary venous PO 2 reduction, and the arteriovenous sinus oxygen content increase were higher than those observed in animals without the blockers. These findings on coronary oxygen content could be due to abolishing a compensatory increase of coronary blood flow to the increased myocardial oxygen consumption related to increased cardiac contractility. In absence of blocking agents, the effects of hCG on cardiac function would overcome the increase of coronary blood flow, which would result in a small reduction of coronary venous PO 2 and a small increase of arteriovenous sinus oxygen content.
Moreover, the present results also showed for the first time that, in addition to exerting coronary vasodilation through ␤ 2 -adrenoceptors, hCG increased coronary blood flow through the augmented endothelial release of NO. The findings obtained about NO are in agreement with those previously reported (17, 22, 34) . Hence, local hCG administration in the anesthetized pigs showed an increased dose-dependent NO release, which was detected as the coronary plasma nitrite level through Griess system (13, 14, 35) . In addition, the coronary effects of hCG were abolished by the local intra-arterial administration of L-NAME, a well-known NOS inhibitor (39) , given at a dose previously used in anesthetized pigs to abolish the vasodilation caused by other hormones (11) (12) (13) (14) .
The results obtained in CEC confirm those observed in the anesthetized pig. The administration of hCG at a concentration that was found in the present study to induce the highest effects and similar to the one used in pigs, acutely increased NO production and the level of phosphorylation of eNOS, ERK, p38, and Akt, which are involved in the intracellular signaling of NO production through ␤-adrenoceptors in CEC (11) (12) (13) (14) 19) . The NO release was detected through the Griess method, which has been previously used to measure changes in NO release in porcine aortic endothelial cells caused by various agents (11-14, 20, 31) . In addition, the effects of hCG on NO release were found to be related to increased cAMP production and the activation of cAMP-PKA signaling, as confirmed by experiments performed with 2=,5=-dideoxyadenosine and H89, which was used at a concentration that was able to prevent the effect of forskolin and similar to the one used in the literature in endothelial cells (11) (12) (13) (14) 33) . Furthermore, the results obtained in the present study show the involvement of PI3K/Akt, ERK/MAPK, and p38/MAPK pathways in the intracellular signaling leading to eNOS activation. In fact, the increased NO synthesis induced by hCG was prevented by the concomitant administration of wortmannin, U-0126, and SB-203580, which were given at doses previously reported to block the intracellular pathways related to ERK, p38, and Akt in endothelial cells (11) (12) (13) (14) (31) (32) (33) . Finally, the ␤ 2 -adrenoceptor agonist and antagonist, salbutamol and butoxamine, given at doses similar to those previously used in endothelial cells and isolated arteries (2, (11) (12) (13) (14) 31) , were able to, respectively, potentiate and abolish the effects of hCG in CEC. On the contrary, the selective ␤ 1 -adrenoceptors agonist, denopamine, did not cause any changes in NO release in CEC. Moreover, since salbutamol potentiated hCG-induced NO release at concentrations that have been reported to occupy almost all ␤ 2 -adrenoceptors (21), the hypothesis of an interaction between hCG and ␤ 2 -adrenoceptors could be excluded.
Thus the role of ␤ 2 -adrenoceptors in NO production could be rather related to the cytoplasmic events downstream hCG receptor activation than to a physical interaction with hCG, as was also suggested by the fact that the effects of salbutamol were prevented by the specific inhibitor of Akt, which acts as an integrator of endothelial ␤ 2 -adrenoceptor-related signal transduction pathways converging on eNOS (19) .
Taken together, the results of this study have shown that hCG, in a similar way as 17␤-estradiol, progesterone, prolactin, and human placental lactogen, can take part in the physiological control of the cardiovascular system during pregnancy by a local modulation of NO release and involvement of the ␤-adrenergic system (29 -31, 39) . The basis of such effects could involve interaction between hCG and LH/hCG receptors, which were found to be expressed in both heart and coronary vessels of pigs.
Further studies would be necessary to clarify the involvement of other factors, such as the renin-angiotensin-aldosterone system and antidiuretic hormone, and to better address the interplay between hCG and other hormones produced in pregnancy.
